Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, UK.
J Immunol Methods. 2012 Oct 31;384(1-2):25-32. doi: 10.1016/j.jim.2012.06.013. Epub 2012 Jun 30.
Nasal allergen challenge can be used to assess the clinical and immunological aspects of rhinitis due to inhalant allergens. We aimed to develop a reproducible technique for grass pollen nasal allergen challenge and to study biomarkers within nasal secretions. 20 Grass pollen allergic individuals underwent nasal challenges with purified Timothy grass allergen. An initial dose-titration challenge was used to determine dose-response characteristics. Subsequently, volunteers underwent 3 further challenges using individualised threshold doses. Symptom scores, visual analogue scores, and peak nasal inspiratory flow (PNIF) were recorded at baseline and up to 6h after challenge. Nasal secretions were collected at each time point using synthetic filter papers or absorptive polyurethane sponges and analysed for IL-4, -5, -10, -13, IFN-γ, Tryptase and Eosinophil Cationic Protein (ECP). Challenges gave reproducible symptom scores and decreased PNIF. Tryptase levels in nasal fluid peaked at 5 min after challenge and returned to baseline levels at 1h. ECP, IL-5, IL-13 and IL-4 levels were increased from 2-3 h and showed progressive increases to 5-6 h. Sponges proved the superior nasal fluid sampling technique. We have developed a reproducible nasal allergen challenge technique. This may be used as a surrogate clinical endpoint in trials assessing the efficacy of treatments for allergic rhinitis. Tryptase in local nasal secretions is a potential biomarker of the early phase response; ECP and the Th2 cytokines IL-5, -13 and -4 markers of late phase allergic responses. Our model allows correlation between clinical responses and local biomarkers following nasal allergen challenge.
鼻变应原激发试验可用于评估吸入性变应原引起的鼻炎的临床和免疫学方面。我们旨在开发一种可重复的豚草花粉鼻变应原激发技术,并研究鼻分泌物中的生物标志物。20 名豚草花粉过敏者接受纯化的Timothy 草过敏原鼻激发。采用初始剂量滴定激发来确定剂量反应特征。随后,志愿者使用个体化阈剂量进行了 3 次进一步的激发。在基线和激发后 6 小时内记录症状评分、视觉模拟评分和峰值鼻吸气流量(PNIF)。使用合成滤纸或吸收性聚氨酯海绵在每个时间点采集鼻分泌物,并分析 IL-4、-5、-10、-13、IFN-γ、类胰蛋白酶和嗜酸性粒细胞阳离子蛋白(ECP)。激发产生了可重复的症状评分和降低的 PNIF。鼻液中的类胰蛋白酶水平在激发后 5 分钟达到峰值,并在 1 小时恢复到基线水平。ECP、IL-5、IL-13 和 IL-4 水平在 2-3 小时内增加,并在 5-6 小时内逐渐增加。海绵被证明是一种优越的鼻液采样技术。我们已经开发了一种可重复的鼻变应原激发技术。这可用于评估治疗过敏性鼻炎的疗效的试验中的替代临床终点。局部鼻分泌物中的类胰蛋白酶是早期反应的潜在生物标志物;ECP 和 Th2 细胞因子 IL-5、-13 和 -4 是晚期过敏反应的标志物。我们的模型允许在鼻变应原激发后对临床反应和局部生物标志物进行相关性分析。